

Requested by Senator LIEBER

**PROPOSED AMENDMENTS TO  
SENATE BILL 628**

1 On page 1 of the printed bill, line 7, after “of” insert “up to three monthly  
2 immunomodulatory courses of intravenous immunoglobulin therapy for the”  
3 and delete “for” and insert “of”.

4 In line 8, after “syndrome,” delete the rest of the line and delete line 9  
5 and insert “when the following conditions have been met:

6 “(a) Clinically appropriate trials, which may be done concurrently, of two  
7 or more less-intensive treatments were:

8 “(A) Not effective;

9 “(B) Not tolerated; or

10 “(C) Did not result in sustained improvement in symptoms, as measured  
11 by a lack of clinically meaningful improvement on a validated instrument  
12 directed at the patient’s primary symptom complex; and

13 “(b) A pediatric subspecialist was consulted and the pediatric subspecial-  
14 ist and the patient’s primary care provider recommend the treatment. For  
15 an adolescent patient, the consultation may be with an adult subspecialist.

16 “(2) The health benefit plan may require that the patient be clinically  
17 reevaluated at three-month intervals.”.

18 In line 10, delete “(2)” and insert “(3)”.

19 On page 4, line 22, delete “the effective date of this 2023 Act” and insert  
20 “January 1, 2025”.